ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 1922 • ACR Convergence 2020

    Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis

    K. Bates Gribbons1, Kaitlin Quinn2, Mark Ahlman3, Peter Merkel4 and Peter C. Grayson5, 1McGovern Medical School UT Houston, Houston, TX, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, 3National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, 4University of Pennsylvania, Philadelphia, PA, 5Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…
  • Abstract Number: 2052 • ACR Convergence 2020

    Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease

    Rona Smith1, David Jayne2 and Peter A. Merkel3, 1University of Cambridge, Cambridge, United Kingdom, 2Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 3Division of Rheumatology University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV).  However, the effect of rituximab is not sustained, and subsequent relapse…
  • Abstract Number: 0092 • ACR Convergence 2020

    Diagnosis of Behçet’s Disease: Comparison of Two Sets of Classification Criteria. Application in 111 Patients of a Well-defined Population

    David Martinez-Lopez1, Alba Herrero Morant2, Carmen Alvarez-Reguera2, Lara Sanchez-Bilbao2, Inigo Gonzalez-Mazon3, José Luis Martín-Varillas4, Guillermo Suarez-Amorin2, Patricia Setien-Preciados2, Cristina Mata-Arnaiz5, Miguel Ángel González-Gay6 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Sierrallana, Torrelavega, Spain, 5Hospital de Laredo, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Behçet’s disease (BD) is a systemic, chronic, relapsing vasculitis with no pathognomonic diagnostic test. The most widely used classification criteria are those of the…
  • Abstract Number: 0510 • ACR Convergence 2020

    Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis

    Marco A. Alba1, Ester Planas-Rigol2, Marc Corbera-Bellalta2, Nekane Terrades-García3, Ana García-Martínez3, Sergio Prieto-González1, Roser Alba-Rovira3, Georgina Espígol-Frigolé1, Javier Marco-Hernández1, Jose Hernández-Rodríguez1, Josep M Grau4 and Maria C. Cid1, 1Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, 2Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, Spain, 3Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, 4Department of Internal Medicine, Hospital Clínic and Fundació Cellex, University of Barcelona, Barcelona, Spain., Barcelona

    Background/Purpose: Giant cell arteritis (GCA) is a large and medium size-vessel granulomatous vasculitis that predominantly affects the aorta and its major branches. The renin-angiotensin-aldosterone system…
  • Abstract Number: 1433 • ACR Convergence 2020

    Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study

    Anna Wilding1, Rona Smith2, David Jayne3, Mårten Segelmark4 and Aladdin Mohammad5, 1Lund University, Staffanstorp, Sweden, 2University of Cambridge, Cambridge, United Kingdom, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 4Lund University, Lund, 5Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden

    Background/Purpose: A higher incidence of thyroid disease has been seen in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aim to assess the incidence…
  • Abstract Number: 1923 • ACR Convergence 2020

    Angiographic Progression of Disease in Large-Vessel Vasculitis

    Kaitlin Quinn1, Himanshu Dashora2, Mark Ahlman3, Elaine Novakovich2 and Peter C. Grayson2, 1Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 3National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD

    Background/Purpose: Angiography is essential to detect vascular disease in patients with large-vessel vasculitis (LVV).  Guidelines differ on the role of periodic angiography to monitor patients…
  • Abstract Number: PP02 • ACR Convergence 2020

    Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease

    Ida Hakkarinen1, 1Vasculitis Patient-Powered Research Network (VPPRN) / Member, Vasculitis Foundation, Greenbelt, MD

    Background/Purpose: For over two years, I experienced a variety of disparate symptoms including:  joint aches, sinus congestion, shortness of breath and chronic cough. An episode…
  • Abstract Number: 0403 • ACR Convergence 2020

    Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair

    Adam Mayer1, Alexandra Sperry2, Laarni Quimson3 and Rennie Rhee4, 1University of Pennsylvania, Internal Medicine/Pediatrics Residency Program, Philadelphia, PA, 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology at the University of Chicago, Chicago, IL, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Around 2-12% of patients who undergo open thoracic aortic aneurysm repair are incidentally found to have aortitis on pathology.  There is no standardized approach…
  • Abstract Number: 0511 • ACR Convergence 2020

    ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses

    Ann Cavers1, Yesim Ozguler2, Olivier Manches3, Arshed Al-Obeidi1, Hua Zhong1, Beatrix Ueberheide1, Gülen Hatemi4, Matthias Kugler1 and Johannes Nowatzky5, 1NYU School of Medicine, New York, 2Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, 3Inserm, U 1209, Grenoble, France, 4Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 5New York University School of Medicine, New York, NY

    Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
  • Abstract Number: 1434 • ACR Convergence 2020

    The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres

    Karl Gisslander1, Lars Dahlin2, Rona Smith3, David Jayne3 and Aladdin Mohammad4, 1Lund University, Lund, Sweden, Lund, Sweden, 2Department of Translational Medicine – Hand Surgery, Lund University, Malmö, Sweden, Malmö, Sweden, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 4Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden

    Background/Purpose: Vasculitis of the peripheral nervous system is seen mainly in systemic vasculitis involving small and medium sized vessels and in cases of single-organ vasculitis…
  • Abstract Number: 1925 • ACR Convergence 2020

    Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis

    Lara Burg1, Peter Brossart2, Charlotte Behning3 and Valentin Schaefer4, 1Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 4Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Ultrasound (US) plays an important role in diagnosis of giant cell arteritis (GCA). To date it is unknown how intima-media-thickness (IMT) of affected arteries…
  • Abstract Number: PP03 • ACR Convergence 2020

    Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships

    Nancy Linn1, Catherine Bammert2, David Bammert3 and Michael Linn4, 1Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, 2MD Anderson, Houston, TX, 3Relapsing Polychondritis Foundation, Houston, TX, 4Relapsing Polychondritis Foundation, New York, NY

    Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
  • Abstract Number: 0404 • ACR Convergence 2020

    Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management

    Nadia Ahmad1, Ayna Verdiyeva2, Raashid Luqmani2 and Shirish Dubey2, 1Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, 2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

    Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
  • Abstract Number: 0514 • ACR Convergence 2020

    Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study

    Kaitlin Quinn1, Himanshu Dashora2, Mark Ahlman3, Elaine Novakovich2 and Peter C. Grayson2, 1Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 3National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD

    Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2).  In these trials, response to…
  • Abstract Number: 1435 • ACR Convergence 2020

    Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis

    Yutaro Hayashi1, Satoshi Hama2, Keisuke Izumi2, Mari Ushikubo1, Misako Konishi3, Yutaka Okano4 and Hisaji Ohshima2, 1Tokyo medical center, Tokyo, Japan, 2Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, 3Tokyo medical center, toukyouto Meguroku, Japan, 4Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan

    Background/Purpose: ANCA-associated vasculitis (AAV) sometimes presents mononeuritis multiplex which worsens the prognosis and activity of daily living in patients. This study aimed to determine theprognostic factorsand…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology